Voya Investment Management LLC Boosts Stock Position in Harrow, Inc. $HROW

Voya Investment Management LLC raised its stake in Harrow, Inc. (NASDAQ:HROW) by 4,035.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 381,461 shares of the company’s stock after purchasing an additional 372,237 shares during the period. Voya Investment Management LLC owned 1.04% of Harrow worth $10,147,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in HROW. Deutsche Bank AG grew its stake in Harrow by 100.9% in the fourth quarter. Deutsche Bank AG now owns 108,064 shares of the company’s stock valued at $3,626,000 after purchasing an additional 54,273 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Harrow by 3.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,356 shares of the company’s stock worth $582,000 after acquiring an additional 585 shares during the last quarter. ProShare Advisors LLC grew its stake in shares of Harrow by 30.8% during the fourth quarter. ProShare Advisors LLC now owns 10,289 shares of the company’s stock worth $345,000 after acquiring an additional 2,421 shares during the last quarter. Rafferty Asset Management LLC purchased a new stake in shares of Harrow during the fourth quarter worth about $270,000. Finally, Two Sigma Investments LP grew its stake in shares of Harrow by 483.2% during the fourth quarter. Two Sigma Investments LP now owns 150,355 shares of the company’s stock worth $5,044,000 after acquiring an additional 124,574 shares during the last quarter. Hedge funds and other institutional investors own 72.76% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on HROW. HC Wainwright boosted their price target on Harrow from $60.00 to $64.00 and gave the stock a “buy” rating in a research note on Wednesday, August 13th. William Blair began coverage on Harrow in a research note on Tuesday, June 10th. They set an “outperform” rating on the stock. Cantor Fitzgerald began coverage on Harrow in a research note on Friday, July 11th. They set an “overweight” rating and a $76.00 price target on the stock. Zacks Research lowered Harrow from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 12th. Finally, BTIG Research boosted their price target on Harrow from $62.00 to $63.00 and gave the stock a “buy” rating in a research note on Thursday, August 14th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, Harrow has an average rating of “Moderate Buy” and a consensus target price of $64.67.

Harrow Trading Up 0.1%

Shares of NASDAQ:HROW opened at $42.88 on Wednesday. Harrow, Inc. has a 12-month low of $20.85 and a 12-month high of $59.23. The company has a market capitalization of $1.59 billion, a PE ratio of -171.52 and a beta of 0.33. The business has a 50 day moving average of $36.58 and a two-hundred day moving average of $30.22. The company has a current ratio of 0.62, a quick ratio of 0.58 and a debt-to-equity ratio of 0.78.

Harrow (NASDAQ:HROW) last announced its quarterly earnings results on Monday, August 11th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.23. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%.The company had revenue of $63.74 million during the quarter, compared to the consensus estimate of $64.23 million. Harrow has set its FY 2025 guidance at EPS. As a group, analysts forecast that Harrow, Inc. will post -0.53 EPS for the current year.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.